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way surface dehydration is a pathological feature of cystic fibrosis
(CF) lung disease. CF is caused by mutations in the CF transmem-
brane conductance regulator (CFTR), a cyclic AMP-regulated Cl
channel controlled in part by the adenosine A2B receptor. An alter-
native CFTR-independent mechanism of fluid secretion is regulated
by ATP via the P2Y2 receptor (P2Y2R) that activates Ca2-regulated
Cl channels (CaCC/TMEM16) and inhibits Na absorption. How-
ever, due to rapid ATP hydrolysis, steady-state ATP levels in CF
airway surface liquid (ASL) are inadequate to maintain P2Y2R-
mediated fluid secretion. Therefore, inhibiting airway epithelial ecto-
ATPases to increase ASL ATP levels constitutes a strategy to restore
airway surface hydration in CF. Using [32P]ATP as radiotracer, we
assessed the effect of a series of ATPase inhibitory compounds on the
stability of physiologically occurring ATP concentrations. We iden-
tified the polyoxometalate [Co4(H2O)2(PW9O34)2]10 (POM-5) as the
most potent and effective ecto-ATPase inhibitor in CF airway epithe-
lial cells. POM-5 caused long-lasting inhibition of ATP hydrolysis in
airway epithelia, which was reversible upon removal of the inhibitor.
Importantly, POM-5 markedly enhanced steady-state levels of re-
leased ATP, promoting increased ASL volume in CF cell surfaces.
These results provide proof of concept for ecto-ATPase inhibitors as
therapeutic agents to restore hydration of CF airway surfaces. As a test
of this notion, cell-free sputum supernatants from CF subjects were
studied and found to have abnormally elevated ATPase activity,
which was markedly inhibited by POM-5.
cystic fibrosis; ecto-ATPases; extracellular ATP; polyoxometalates;
purinergic receptors
INTRODUCTION
The mucus gel layer covering the airway surface periciliary
layer (PCL) traps inhaled materials and also acts as a reservoir
for water, buffering hydration of the PCL for needed cell-
surface lubrication and efficient ciliary beating. Airway surface
liquid dehydration and the production of hyperconcentrated
mucus lead to airway obstruction and are pathological features
of cystic fibrosis (CF), chronic obstructive lung disease
(COPD), and asthma. Airway surface hydration is maintained
by water fluxes driven by the balance between active Cl
secretion versus Na absorption.
CF is caused by a genetically deficient production/function
of the CF transmembrane conductance regulator (CFTR) pro-
tein, a cyclic AMP-regulated airway epithelial Cl channel. In
normal airways, fluid transport is regulated in part by airway
surface liquid (ASL) concentrations of adenosine (Ado) acting
on the airway epithelial Gs-coupled A2B receptor (A2BR),
which promotes Cl secretion via cyclic AMP-regulated
CFTR activation (20, 21). The Gq-coupled P2Y2 receptor
(P2Y2R), which is activated by ATP, provides additional
mechanisms for CFTR activation via protein kinase C (17) and
Ca2 stimulation of adenylyl cyclase (26). However, due to the
genetically deficient production/function of CFTR, these
mechanisms are inoperative in CF. An alternative CFTR-
independent pathway for water transport is provided by the
P2Y2R via the Ca2-activated Cl channel CaCC/TMEM16
and inhibition of Na absorption (19).
Mechanisms that sense surface hydration tune the nucleotide
release and extracellular hydrolysis pathways to regulate ATP
and Ado levels in ASL (5). ATP is released onto the luminal
surface from 1) ciliated cells via the apical membrane channel
pannexin 1 (32, 35) and 2) goblet cell mucin granules via
vesicular nucleotide transporter (VNUT)-mediated transport
(36). Once released, ATP can interact with P2Y2R but is also
rapidly converted to Ado by cell-surface ecto-nucleotidases.
While a body of literature, including our own studies, indicates
that ATP release rates are not altered in CF (14, 21, 28, 34, 40,
42), ecto-ATPases in CF maintain ASL ATP levels below
threshold values for P2Y2R activation (21, 27). Consequently,
the CFTR-independent mechanism downstream of P2Y2R can-
not optimally regulate ASL hydration throughout the lung in
CF (21).
Restoration of ASL hydration is a goal of CF therapies but
remains difficult to achieve due to the complexity of the
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regulatory systems that maintain ASL homeostasis. One strat-
egy to restore ASL volume in CF airway surfaces is to raise the
effective level of nucleotides in airway surfaces. One approach
to achieve this goal was to aerosolize relatively ecto-ATPase-
resistant dinucleotides (denufosol) onto CF airway surfaces.
This approach was limited by the receptor desensitization
produced by delivery of high concentrations of these agents
onto airway surfaces (5). An alternative approach to raising
steady-state ATP levels on airway surfaces is to inhibit the
metabolism of endogenously released ATP. However, effective
inhibitors of ATP hydrolysis in CF airways have not been
identified, due, in part, to the complex array of ATP metabo-
lizing ectoenzyme activities expressed on airway surfaces.
Three major families of ecto-nucleotidases hydrolyze extra-
cellular ATP: 1) ecto-nucleoside triphosphate diphosphohydro-
lases (ENTPDs); 2) ecto-nucleotide pyrophosphatases/phos-
phodiesterases (ENPPs); and 3) nonspecific alkaline phospha-
tase (NSAP) (43). ENTPDs are two-transmembrane domain
proteins with large extracellular loops harboring catalytic sites.
ENTPDs hydrolyze ATP and ADP, producing AMP and inor-
ganic phosphate (Pi) as final hydrolysis products. ENTPDs are
composed of four subtypes (ENTPD1 or CD39, ENTPD2,
ENTPD3, and ENTPD8), and each hydrolyzes ATP and ADP
at different rates (43). ENPPs remove pyrophosphate (PPi)
from ATP, producing AMP. ENPP1 and ENPP3 contain a
single transmembrane domain, while ENPP2 is a secreted
enzyme. NSAP is a glycosylphosphatidylinositol-anchored
protein that dephosphorylates ATP, ADP, and AMP, generat-
ing adenosine (43). Members of these three families of ecto-
ATPases are expressed in airway epithelia (4, 29, 30). In
addition to cell-associated activities, ATPases also can be
secreted from submucosal glands (10) or shed into the airways
by epithelial or inflammatory cells, e.g., with exosomes (7),
likely contributing as “soluble” enzymes to ATP depletion in
ASL in vivo (2, 18, 37). Thus, secreted/shed ATPases further
shield the P2Y2R from bulk phase nucleotides, greatly dimin-
ishing the effectiveness of released ATP to hydrate intralumi-
nal mucus in CF.
In the present study, we assessed ATP hydrolysis under
first-order kinetics, i.e., using trace amounts of [32P]ATP
[(ATP)  Km], which most closely predicts the decay pattern
of physiologic concentrations of ATP occurring in ASL (21).
Using this approach, we screened a series of ecto-ATPase
inhibitor structures to identify molecules that potently and
effectively reduce ATP hydrolysis in CF airway epithelia and
CF lung secretions. We then tested the hypothesis that, by
enhancing steady-state levels of released ATP, ATPase inhib-
itors promote increased ASL volume production in CF cells.
METHODS
Cell cultures and incubations. Primary (P0) human bronchial
epithelial cells (HBEC) from normal subjects and CF subjects were
obtained from the University of North Carolina (UNC) CF Center
Tissue Culture Core. Cells were differentiated into air-liquid interface
(ALI) preparations for 5–7 days on collagen-coated 12-mm Transwell
permeable supports (Costar) and subsequently maintained for 4–5 wk,
as previously described (21, 35). All cultures used exhibited a 508/
508 CFTR genotype, which is the most common CFTR mutation.
Sputum and subjects. Induced sputum was collected from 15
healthy and 11 CF subjects (Table 1) and cell-free sputum superna-
tants were obtained as previously described (2, 15). Studies were
approved by the UNC Institutional Review Board (IRB no. 06-0979),
and all participants provided written informed consent.
ATP hydrolysis. Measurements with HBECs were performed as
previously described (21). Briefly, cultures were maintained in (ba-
solateral) ALI medium and the apical surface rinsed (3) with PBS
and preincubated for 1 h with 250 L Hanks’ balanced salt solution
(HBSS) supplemented with 2 mM CaCl2 and 2 mM MgCl2 and
buffered with 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES; 25 mM pH 7.4). To assess ATP hydrolysis under first-order
kinetics, incubations were initiated by the addition of 2 L 0.1 Ci
[32P]ATP (Perkin-Elmer; S.A. 	 3,000 Ci/mmol); no ATP mass was
added to these incubations At the times indicated, 10 L mucosal
solutions were transferred to 1.5-mL Eppendorf tubes containing 100
L 1 mM ATP, heated at 95°C for 2 min to inactivate potential
ATPase activities shed from cells, cooled on ice, and analyzed by
HPLC (see below). To assess the rates of hydrolysis of various ATP
concentrations, 0.03–1.0 mM ATP was added to cells concurrently
with [32P]ATP and aliquots were collected at 2, 5, 15, 30, and 60
min. The initial rate of ATP hydrolysis was calculated from incuba-
tions that exhibited 10% [32P]ATP hydrolysis. For experiments
with ATPase inhibitors, 25 L vehicle or drugs (10) were added to
cells 10 min prior to addition of [32P]ATP. To measure ATP
hydrolysis in sputum supernatants, 5 L 0.1 Ci [32P]ATP was
added to 45 L ice-cold sputum supplemented with 2 mM CaCl2, 2
mM MgCl2, and 25 mM HEPES pH 7.4 and vehicle/inhibitor as
indicated. Samples were incubated at 37°C for 15 min. Reactions were
terminated by transferring samples to ice followed by the addition of
100 L 1 mM ATP and heated at 95°C, as above.
32P-labeled species were quantified via a Waters HPLC using a
Symmetry C15 5-m (4.6  150 mm) column eluted with 1 mL/min
of a mobile phase consisting of 100 mM KH2PO4 and 8 mM
tetrabutylammonium bisulfate in 20% methanol pH 5.3. Elution times
of 32P-labeled species were 32Pi, 2.3 min; 32PPi, 3.1 min; and
[32P]ATP, 5.3 min.
ATP release. To promote acute ATP release, HBECs were sub-
jected to hypotonic cell swelling, as previously described (35).
Briefly, the apical surface was rinsed and preincubated undisturbed for
1 h in 100 L luminal HBSS. In the absence/presence of 100 M
polyoxometalate-5 (POM-5), 100 L saline or H2O were added to
cells. After 5 min, 100 L of the apical solution was removed,
transferred to tubes containing 100 L ice-cold H2O, heated at 95°C
as above, and stored at 80°C until further analysis. To induce
chronic shear stress-promoted ATP release, cultures were subjected to
phasic motion for 1 h in 60 L HBSS in the presence or absence of
100 M POM-5 (5). At the end of the incubation, 30 L ASL were
Table 1. Subject demographics
Demography Controls CF
N 15 11*
Age, yr 25.9 
 6.1 30.3 
 10.8
Sex, % male 73.3 41.7
Race, % Caucasian 73.3 100
FVC, % predicted† 102.0 
 10.6 65.8 
 19.8
FEV1, % predicted† 83.7 
 34.3 49.5 
 15.4
FEV1/FVC† 81.2 
 5.6 70.9 
 11.6
FEF 25–75, % predicted† 83.8 
 19.0 25.1 
 13.8
Sputum PMNs, cells/mg plug‡ 334 
 314 18,645 
 12,766
Values are means 
 SD. *Genotype data indicate that 9 cystic fibrosis (CF)
sputum donors expressed either the 508/508 CFTR mutation or 508/other
mutation; the other 2 subjects expressed G551/R334 and S549/S549, respec-
tively. †Values are prebronchodilator for controls and postbronchodilator for
subjects with CF. ‡PMN data available for 13 controls and 8 subjects with CF.
FVC, force vital capacity; FEV1, force expiratory volume (1 s); FEF 25–75,
force expiratory flow at 25%–75% FVC; PMN, polymorphonuclear leukocytes
(neutrophils).
transferred to tubes containing 170 L ice-cold H2O and processed as
above.
Quantification of adenine nucleotide concentrations. Concentra-
tions of ATP, ADP, AMP, and adenosine were measured by a
modification of the etheno-derivatization technique previously de-
scribed (21). Briefly, 200 L samples were incubated with 0.5 M
2Cl-acetaldehyde in citrate-phosphate buffer pH 4.0 (45 min, 80°C),
and the resulting fluorescent etheno species were separated by HPLC
(injection volume  50 L) via an RP-18c Chromolith column (11).
Ethenylated (e) species were eluted as follows: eAMP, 2.47 min;
eAdo, 3.22 min; eADP, 4.13 min; eATP, 6.99 min.
ASL height. Cells were maintained at an air-liquid interface over-
night under phasic motion (0.5 dyn/cm2, 14 cycles/min) (5). After-
ward, PBS or PBS containing 1 mM POM-5 was applied via an
Aeroneb Laboratory Nebulizer [final (POM-5)  100 M; volume
applied  100 nL], and ASL height was measured by confocal mi-
croscopy, as in Ref. 5.
Real-time PCR analysis. Total RNA was isolated using the Zymo
Direct-zol RNA mini prep kit and 500 ng RNA were reverse-
transcribed into cDNA using Superscript II. RT-PCR for ENTPD1,
ENTPD2, ENTPD3, ENTPD8, and NSAP was performed using
TaqMan Gene Expression Assays from Applied Biosystems.
GAPDH was used as a reference gene.
Transepithelial resistance (RT) was measured via an EVOM2 epi-
thelial volt ohm meter, as described (9).
Reagents. 4,4=-Diisothiocyano-2,2=-stilbenedisulfonic acid (DIDS),
pyridoxal phosphate-6-azophenyl-2=,4=-disulfonic acid (PPADS),
,-MetATP, and levamisol were purchased from Sigma-Aldrich (St.
Louis, MO). DIDS was obtained from Toronto Research Chemicals
(Toronto, ON, Canada). POM-1 (Na6[H2W12O40].21H2O), NF 279,
PSB 06126, PSB 069, and ARL 67156 were from Tocris Biosciences
(Minneapolis, MN). POM-4 (K6H2[TiW11CoO40].13H2O), POM-5
(K10[Co4(H2O)2(PW9O342)2].22H2O), and POM-6 ((NH4)18[NaSb9-
W21O86].14H2O) were prepared according to published procedures
(22, 24). Other chemicals were from sources reported previously (21).
Statistics. Except when indicated otherwise, comparisons between
sample groups were tested with independent t tests (JMP Pro-12).
Because of overall small sample sizes, no adjustments for multiple
comparisons were made. P value  0.05 was considered significant.
All results are presented as mean 
 SD.
RESULTS
ATP hydrolysis in HBEC ASL. The stability of radiotracer
amounts of [32P]ATP was assessed in ASL bathing non-CF
and CF HBEC. [32P]ATP hydrolysis exhibited first-order
kinetics with similar rate constants (k) in non-CF and CF cells
and comparable half-live values (non-CF, t1/2  1.9 min; CF,
t1/2  1.4 min) (Fig. 1). In both CF and non-CF HBEC, 32Pi
was the sole product of [32P]ATP hydrolysis, i.e., at no time
was the formation of 32PPi observed. The absence of 32PPi
accumulation was not due to PPi degradation (PPi¡2Pi), as
32PPi added to cells remained unaltered after 60 min (not
shown). These results suggest that ecto-ATPases other than
ENPPs (e.g., ENTPDs and/or NSAP) are responsible for the
rapid ATP depletion observed in non-CF and CF HBEC ASL.
ENTPD and NSAP expression in HBEC. The relative abun-
dance of ENTPDs and NSAP was assessed via real-time PCR
analysis. ENTPD3 and NSAP were the predominant ATPase
genes amplified in control and CF cells. ENTPD1 and ENTPD2
were also amplified in control and CF HBEC but with apparently
lower abundance than ENTPD3 (Fig. 2). ENTPD8 expression
was below detection limit, i.e., the amplification signal was
undistinguished from background after 35 PCR cycles. No
differences were observed between control and CF cells in the
levels of expression of these genes (Fig. 2).
Screening for inhibitors of ATP hydrolysis in airway
epithelia. Ecto-ATPase inhibitors described in the literature
derive from the following chemical classes: 1) nucleotides and

















Fig. 1. Decay of [32P]ATP on human bronchial epithelial cells (HBEC).
Incubations were initiated by the addition of 0.1 Ci [32P]ATP to 250 L
HBSS bathing the luminal surface of non-cystic fibrosis (CF) and CF HBEC
cultures. Aliquots were removed at the time indicated and the resulting
32P-labeled species were quantified by HPLC, as described in METHODS. The
data represent the mean 
 SD from three experiments. Exponential decay lines
were generated, and first-order rate constant values were calculated (non-CF,

























Fig. 2. RT-PCR of ecto-nucleoside triphosphate diphosphohydrolase (ENTPDs)
and nonspecific alkaline phosphatase (NSAP) in human bronchial epithelial
cells (HBEC). mRNA quantification was performed in HBEC cultures from
four non-cystic fibrosis (CF) (control, CTL) and four CF donors. Values were
log transformed to achieve normality, and mean differences between CF and
non-CF HBEC data were assessed with linear mixed models, with a sample as
random effect factor (R package, nlme). The data were plotted using the
2(CT) transformation [CT, threshold cycles (33)]. The mean value for CTL
ENTPD1 expression was used as relative baseline value. ENTPD3 and NSAP
were significantly different from ENTPD1 and ENTPD2. *P  0.05; **P 
0.001; ***P  0.0001.
analogs (e.g., ARL 67156, ,-MetATP); 2) sulfonated dyes/
anthraquinone derivatives (e.g., Reactive Blue, PSB 06126)
(3); 3) suramin (a hexasulfonated naphthylurea) and analogs
(e.g., NF 279) (25); and 4) polyoxometalates (POMs) (22).
Additional molecules exhibiting ATPase inhibitory activity
include the stilbene disulfonate DIDS (12) and pyridoxal phos-
phate-6-azophenyl-2=,4=-disulfonic acid (PPADS) (16). Lastly,
levamisol (imidazothiazole derivative) is an effective although
weak inhibitor of NSAP (30). The reported selectivity of these
inhibitors toward ecto-ATPases is summarized in Table 2.
As an initial screen to identify candidate molecules that
inhibit ATP hydrolysis in HBEC ASL, the effects of members
of the above mentioned chemical groups on [32P]ATP hydro-
lysis were investigated. Because of the limited availability of
primary cultures of CF cells, our initial screen used HBEC
from non-CF donors.
As shown in Fig. 3, nearly 80% of the initial [32P]ATP
administrated to cells was hydrolyzed within 5 min. Levamisol
had little to no effect on this hydrolysis, ruling out contribu-
tions of NSAP. The nonspecific ENPP inhibitor ,-MetATP
also had negligible effects on [32P]ATP hydrolysis. NF 279,
which was shown to inhibit ENTPDs (25), markedly reduced
ATP hydrolysis after the initial 5–15 min, but 97% [32P]ATP
was hydrolyzed after 60 min. PPADS, a P2XR antagonist
shown to inhibit rat ENTPD1 and ENTPD2 (16), also delayed
but did not prevent ATP hydrolysis. Similarly, ARL 67156, a
relatively weak inhibitor of ENTPDase1 and ENTPD3 that has
no effect on ENTPD2 (23, 24), showed a partial and transient
effect. A more robust inhibition of [32P]ATP hydrolysis was
observed with PSB 06126, DIDS and, most sustainable,
POM-1 (Fig. 3). The DIDS analog SITS displayed no effect at
all on ATP hydrolysis (not shown). Attempts to test for the
effect of the PSB 06126 analog PSB-069 were unsuccessful
due to its poor solubility in aqueous solutions (3).
POM-5 is a potent and effective inhibitor of ATP hydrolysis
in HBEC. Recently, various POMs have been evaluated and
shown to exhibit similar or more potent inhibition, relative to
POM-1, on recombinant ecto-ATPases (22). Accordingly, the
effects of POM-1, POM-4, POM-5, and POM-6 were exam-
ined in both non-CF and CF HBEC. POM-4 and POM-5
exhibited more robust and long-lasting inhibition of ATP
hydrolysis than POM-1 and POM-6 in both non-CF and CF
HBEC; 50–80% of the initial [32P]ATP was recovered after 60
min in the presence of POM-4 or POM-5. No major differences
were observed between non-CF and CF HBEC regarding POM
inhibition (Fig. 4).
Inhibitor concentration-effect relationships for [32P]ATP hy-
drolysis on HBEC indicated that POM-5 was a more potent
inhibitor (IC50  4.8 M) than POM-6 (IC50  9.8 M) and
POM-4 (IC50  10.6 M), whereas POM-1 exhibited rela-
tively weaker inhibition (IC50  32.1 M) (Fig. 5A). To gain
further insight into the nature of POM-5 inhibition, the initial
rates of hydrolysis of various ATP concentrations were deter-
mined in the absence or presence of 30 M POM-5. In naïve
cells, ATP hydrolysis rates increased exponentially with sub-
strate concentration, but changes in hydrolysis rates were
blunted by 30 M POM-5 (Fig. 5B). The minor effect of
substrate concentration on POM-5 inhibition suggests that
POM-5 either acts as a noncompetitive inhibitor or exhibits an
affinity for ENTPDs that is considerably higher than ATP, as
reported with POM-1 in cerebellar slices (41). In addition, as
shown with POM-1 in cerebellum (41), POM-5 inhibition of
ATP hydrolysis in HBEC was largely reversible upon remov-
ing the inhibitor from cells. Incubation of HBEC with 30 M
POM-5 resulted in robust inhibition of [32P]ATP hydrolysis,
but hydrolysis returned to near (although not identical to)
control values in cells that were incubated with 30 M POM-5,
then washed and incubated with [32P]ATP (Fig. 5C).
POM-5 markedly reduces the hydrolysis of released ATP.
The effectiveness of POM-5 to prevent the metabolism of
released ATP was assessed in HBEC subjected to acute (5 min)
hypotonic cell swelling (27, 35). To assess the pattern of
nucleotide/nucleoside distribution following hypotonicity-in-
duced ATP release, the entire spectrum of adenine nucleotides/
Table 2. Reported selectivity of ATPase inhibitors
Inhibitor Enzyme Selectivity Reference
ARL 67156 ENTPD1 	 ENTPD3 (24, 25)
,-MetATP ENPP* (18)
PSB 06126 ENTPD3r (3)
NF 279 ENTPD1, ENTPD2, ENTPD3, ENTPD8 (26)
DIDS Unidentified ATPase† (12)
PPADS ENTPD1r, ENPPsr (16)
Levamisol NSAP‡ (31)
POM-1 ENTPD, ENTPD2, ENTPD3, ENPP1 (23)
POM-4 ENTPD1, ENTPD2, ENTPD3, ENPP1,
ENPP2, ENPP3, NSAP
(23)
POM-5 ENTPD1, ENTPD2, ENTPD3, ENPP1 (23)
POM-6 ENTPD2, ENTPD3, ENPP1 (23)
*Endogenously expressed in rat PC12. †Endogenously expressed in rat
parotid. ‡Endogenously expressed in human bronchial epithelial cells. rRat,
recombinant; all the others are human, recombinant. ENPP, ecto-nucleotide
pyrophosphatase/phosphodiesterase; ENTPD, ecto-nucleoside triphosphate
diphosphohydrolase; NSAP, nonspecific alkaline phosphatase; POM, polyoxo-
metalate; PPADS, pyridoxal phosphate-6-azophenyl-2=,4=-disulfonic acid.
























Fig. 3. Effect of ATPase inhibitors on ATP hydrolysis in human bronchial
epithelial cells. Cells were incubated with [32P]ATP as in Fig. 1 in the
absence or presence of the indicated drug. All inhibitors were at 100 M final
concentration, except levamisol (10 mM). The data indicate the mean 
 SD
from 2–4 independent experiments. POM, polyoxometalate; PPADS, pyri-
doxal phosphate-6-azophenyl-2=,4=-disulfonic acid.
nucleosides in ASL was quantified using the etheno-derivati-
zation technique (21). In static, vehicle-treated HBECs, con-
centrations of ADP (~145 
 46 nM) and AMP (255 
 47 nM)
were markedly higher than ATP (7 
 3 nM) and Ado (8 
 17
nM) (Fig. 6). ATP represented 2% of the total extracellular
nucleotide/nucleoside pool in static cells. Hypotonic challenge
produced a 3-fold increase of total extracellular nucleotides in
both vehicle-treated and POM-5-treated cells (net increase of
~800 nM). However, striking differences in nucleotide distri-
butions were observed with POM-5 treatment. In the absence
of POM-5, levels of Ado, AMP, and ADP markedly increased
(to 114 
 18 nM, 433 
 54 nM, and 702 
 103 nM, respec-
tively), but ATP levels remained in the low nM range (13 
 5
nM). In contrast, in the presence of POM-5, ATP levels
increased 	50-fold (isotonic, 10 
 3 nM; hypotonic, 552 

110 nM) and represented nearly 60% of the newly released
adenine purine pool (Fig. 6). These findings indicate that
POM-5 greatly (although not completely) reduced the ability of
ENTPDs to hydrolyze ATP upon its release from cells.
POM-5 improves ASL volume regulation in CF HBEC cells.
The ultimate goal of our study was to identify reagents that, by


























Fig. 4. Effect of polyoxometalates (POMs) on ATP
hydrolysis on non-cystic fibrosis (CF) (A) and CF
(B) human bronchial epithelial cells. Cells were
incubated with [32P]ATP as in previous figures.
POMs (100 M) were added to cells 10 min prior
to [32P]ATP. The data represent the mean 
 SD




































































Log [inhibitor] (μM) [ATP] (μM)
Fig. 5. Polyoxometalate (POM)-5 is a potent, noncompetitive, reversible inhibitor of ATP hydrolysis in human bronchial epithelial cells. A: hydrolysis of
[32P]ATP was assessed for 15 min in the presence of the indicated concentration of POM-1, POM-4, POM-5, or POM-6. B: the initial rates of hydrolysis of
30, 100, 300, and 1,000 M ATP were measured in the absence or presence of 30 M POM-5. The data in A and B represent the mean 
 SD from two
experiments performed with duplicate samples. The sigmoidal curves (A) and exponential rise regression lines (B) were fitted using Sigma Plot 10. C: inhibition
of ATP hydrolysis is greatly reversed upon removal of POM-5: open squares, cells were preincubated (30 min) with POM-5 and then washed and incubated with
[32P]ATP in the absence of POM-5 for 15 min; closed squares, naïve cells were incubated with [32P]ATP in the presence of 30 M POM-5. The data are
expressed as % ATP hydrolysis relative to cells that were not exposed to POM-5. Values (mean 
 SD; n  4 per condition) are representative of three
independent experiments. *P  0.05; **P  0.001.
fluid transport in CF cells. Therefore, the effect of POM-5 on
ASL volume regulation was investigated in CF HBEC. Cells
were incubated overnight under oscillatory shear stress that
mimics the phasic motion of the lung in vivo (6, 39, 40),
following which 100 nL 1 mM POM-5 was apically adminis-
trated via nebulization [final (POM-5)  100 M], as de-
scribed (5). Confocal microscopy was used to measure ASL
heights as an index of ATP-mediated fluid secretion (Fig. 7A
and Ref. 5). As we previously reported (40), shear stress-
stimulated CF HBEC exhibited an ASL height of ~5–7 m
(Fig. 7, A and B), which is markedly lower than the ~14-m
height measured in normal HBEC under similar conditions
(40). Notably, POM-5 increased ASL height in phasic motion-
stimulated CF HBEC to ~15–20 m, and ASL height remained
elevated after 2 h in the presence of POM-5 (Fig. 7B). In
parallel measurements, a 	3-fold increase of ASL ATP con-
centration was observed in CF HBEC subjected to phasic
motion in the presence, but not absence, of POM-5 (Fig. 7C).
Control measurements indicated that POM-5 did not affect
the transepithelial resistance (Table 3). Furthermore, the fact
that no radioactivity was detected in the basolateral medium
after 1 h of the combined addition of [32P]PATP and POM-5 to
the mucosal bath (not shown) suggests that POM-5 did not
affect the monolayer integrity.
Increased ATPase activity in CF airway secretions. Studies
with cell cultures may not completely describe the mechanisms
of nucleotide-regulated ASL hydration in vivo. For example,
we have previously reported that sputum from subjects with CF
exhibited enhanced ATP hydrolysis rates relative to controls
(37). This observation suggests that ecto-ATPases secreted/
shed from airway epithelial and/or inflammatory cells in CF
airways in vivo also contribute to ATP depletion in ASL,
further reducing the effectiveness of released nucleotides to
hydrate intraluminal mucus in CF lungs. Therefore, we inves-
tigated associations between ATPase activities and nucleotide/
nucleoside distribution in sputum supernatants from control
and CF subjects.
The total quantity of purines in CF sputa (2.4 
 1.4 M,
mean 
 SD) was fourfold higher than in control sputa
(0.6 
 0.4 M), suggesting that nucleotide release is upregu-
lated in CF airways, e.g., via VNUT nucleotide transporter
upregulation (28). However, while AMP and ADP levels were
elevated in CF sputa, ATP concentration in CF samples
(0.006 
 0.001 M) was markedly reduced (	20 lower)
relative to healthy controls (0.16 
 0.05 M) (Fig. 8A). Nota-
bly, ATP comprised 26% of the total nucleotide pool in control
samples but only 0.25% of the total pool in CF (Fig. 8A). These
data suggest that the reduced levels of ATP observed in CF
secretions likely reflect increased ATP hydrolysis.
Direct measurements of [32P]ATP hydrolysis in sputum
supported this hypothesis. Incubation of CF sputum super-
natants with [32P]ATP for 15 min resulted in robust
(53.5 
 12.5%, mean 
 SD) conversion of [32P]ATP to 32Pi.
In contrast, 11.9 
 22% conversion was observed in control
sputa (Fig. 8B). Similar to our findings with HBEC, 32Pi was
the sole product of [32P]ATP hydrolysis in sputum (not

























Fig. 6. Polyoxometalate (POM)-5 reduces the hydrolysis of released ATP.
Human bronchial epithelial cells were subjected to hypotonic cell swelling for
5 min in the presence of 100 M POM-5 (or vehicle, PBS), and adenosine
(Ado), AMP, ADP, and ATP were quantified by etheno-derivatization and
HPLC analysis, as indicated in METHODS. The scatter plots indicate the
mean 
 SD, n  4 per condition. *P  0.009; **P  0.0033; ***P  0.0005


































Fig. 7. Polyoxometalate (POM)-5 improves airway surface liquid (ASL) volume regulation in cystic fibrosis (CF) human bronchial epithelial cells (HBEC). ASL 
height and nucleotide levels were measured in CF HBEC subjected to phasic motion, as described in METHODS. A: representative confocal microscopy image taken 
at 60 min in the absence (PBS) or presence of 100M POM-5. Bar  10m. B: quantification of ASL height in CF HBEC. The data represent the mean SD 
from 10 images/culture (4 cultures/condition; *P  0.05) and are representative of two independent experiments. C: ATP release was measured in cells bathed 
with 60L PBS with/without 100M POM-5 for 60 min under phasic motion. The scatter plots indicate the mean SD (*P  0.05) from four CF HBEC 
cultures and are representative of two independent experiments.
abolished by POM-5 and markedly reduced by POM-1,
POM-4, and POM-6 but was not affected by levamisol (Fig.
8C). Collectively, these data suggest that ATP hydrolysis in CF
sputum is driven by members of the ENTPD family of ecto-
ATPases.
DISCUSSION
By rapidly dephosphorylating ATP (and ADP), ecto-ATPases
generate AMP and facilitate the formation of adenosine, lead-
ing to A2BR-promoted cyclic AMP-regulated CFTR activity.
This pathway results in sustained regulation of water fluxes in
normal airway epithelia. However, adenosine/A2BR-mediated
signaling fails to promote airway hydration in CF (21). Fur-
thermore, by reducing ASL ATP levels, ecto-ATPases limit the
ability of airway epithelia to promote fluid secretion via
P2Y2R-mediated CaCC Cl channel activity and inhibition of
epithelial Na channel, dampening an otherwise key compen-
satory mechanism for fluid secretion in CF cells. Therefore, we
hypothesized that inhibition of ATPase activities would facil-
itate ASL hydration in CF.
We tested this hypothesis by utilizing a [32P]ATP hydrolysis
assay that, by closely predicting the decay of naturally occur-
ring ASL ATP, allowed us to 1) identify molecules that
potently and efficaciously reduced ATP hydrolysis in CF
airway epithelial cells and increased the stability of released
ATP and 2) demonstrated that inhibition of ATP hydrolysis led
to increased ASL volume secretion onto CF airway epithelial
cells.
As described in the present study (Fig. 1), ATP hydrolysis
on airway surfaces exhibited first-order kinetics with rate
constant and half-life values that were similar in CF and
non-CF cells (Fig. 1). These data suggest that the CFTR defect
Table 3. POM-5 has no effect on transepithelial cell
resistance
RT, /cm2
Minutes PBS 100 M POM-5
0 1,097 
 127 1,013 
 12
5 816 
 188 1,383 
 237
30 1,170 
 244 956 
 108
60 780 
 141 988 
 106
120 885 
 140 1,004 
 25
Values are means 
 SD; n  3/group. Transepithelial resistance (RT) was
measured in human bronchial epithelial cells via an EVOM2 epithelial volt

































































Fig. 8. Enhanced ATPase activity in cystic fibrosis (CF)
sputum. A: nucleotide levels in control (n  15) and CF (n 
11) sputum supernatants are expressed as mean 
 SD. *P 
0.004 and **P  0.0002, relative to control. B: [32P]ATP
was added to sputum supernatants from 15 controls and 11
subjects with CF for 15 min (37°C), and the resulting %
hydrolysis is expressed as mean 
 SD. *P  0.0005. C:
effect of polyoxometalates (POMs) and levamisol on ATP
hydrolysis in CF sputum. The data (mean 
 SD from 7 CF
sputum samples) represent the % ATP hydrolysis observed
in the presence of vehicle, 100 M of the indicated POM,
or 10 mM levamisol (Levam), *P  0.0007 and **P 
0.0001 against vehicle (paired t test). Ado, adenosine.
inherent to CF cells does not directly affect the stability of
physiologically occurring ATP levels in ASL. Our real-time
PCR analyses, indicating no difference in expression levels of
ENTPDs and NSAP between CF and non-CF cells, support the
functional data.
An important finding of our study was the identification of
POMs as potent inhibitors of ATP hydrolysis in airway epi-
thelial cells. Polyoxometalates are anionic metal-oxides of
early transition metals that, due to their negative charge, bear
resemblance to nucleotides. This enables them to selectively
block enzymes such as nucleotidases (38). Using membrane
preparations isolated from COS-7 cells overexpressing human
ecto-ATPases, Lee and collaborators (22) identified POM-5 as
the most potent inhibitor ENTPD1, ENTPD2, and ENTPD3;
POM-5 also inhibited ENPP1 but had no effect on ENPP2,
ENPP3, and NSAP. POM-4 was the second most potent
inhibitor of ENTPD1, ENTPD2, and ENTPD3 and also inhib-
ited ENPP1, ENPP2, ENPP3, and NSAP. POM-1 inhibited
ENTPD1, ENTPD2, and ENTPD3, but with markedly lower
affinity (20–200-fold higher Ki values) than POM-4 and
POM-5 (22). POM-6 inhibited ENTPD2 and ENTPD3 with
affinities similar to POM-1 but was a weak and partial inhibitor
of ENTPD1 [38% inhibition at 20 M (22)]. None of these
POMs inhibited ENTPD8 (22). Our results indicating 1) potent
and strong inhibitory action of POM-5; 2) lack of effect of the
NSAP inhibitor levamisol; and 3) absence of formation of
32PPi following the addition of [32P]ATP to cells led us to
hypothesize that ENTPD1, ENTPD2, and/or ENTPD3 were
responsible for ATP hydrolysis on HBEC. Furthermore, PSB
06126, a potent and highly selective inhibitor of rat ENTPD3
(3), markedly delayed (but did not prevent) [32P]ATP hydro-
lysis in HBEC (Fig. 3), suggesting that ENTPD3 is one
important (but not the only) contributor. Unambiguous eluci-
dation of the roles of ENTPD1, ENTPD2, and ENTPD3 in the
regulation of ATP concentrations in ASL will require the
development of selective inhibitors of these enzymes and/or
the use of molecular approaches to knockdown/knockout these
molecules.
Importantly, 	60% of the initial [32P]ATP was recovered
intact in ASL in the presence of POM-4 and POM-5 after 1 h
(Fig. 3), suggesting that these POMs markedly prolong the
stability of physiologically relevant concentrations of ATP.
Indeed, POM-5 enhanced ATP levels resulting from acute cell
swelling-promoted ATP release (Fig. 6). Notably, in response
to prolonged, physiologically relevant stimulation, i.e., shear
stress-promoted ATP release, POM-5 increased ATP levels
and produced rehydration of ASL in CF HBEC (Fig. 7). This
observation provides a proof of concept for the use of ENTPD
inhibitors as therapeutic agents to restore ASL volume regula-
tion in CF cells.
The mechanisms of nucleotide-regulated ASL hydration in
inflamed CF airways are more complex than those described in
CF cells cultured in the absence of an inflammatory/infectious
environment. To mimic the in vivo CF environment, HBEC
have been chronically exposed to CF-relevant inflamed envi-
ronments, e.g., sterile supernatants of mucopurulent material
(SMM) from CF lungs. Notably, SMM-exposed cell cultures
exhibited mucus hyperproduction (1, 13) and enhanced expres-
sion of ENTPD3 (13). Although not assessed here, the en-
hanced ENTPD3 activity associated with SMM-inflamed
HBEC is predicted to be inhibited by POMs, most potently by
POM-5 (22). However, we did study CF sputum. Our data
showed that cell-free sputum supernatants from subjects with
CF exhibited markedly (	20) decreased concentrations of
endogenous ATP and increased levels of AMP and ADP,
consistent with increased ATPase activity (Fig. 8). These
supernatant data suggest that, in addition to cell-bound activ-
ities, ATPases either secreted from submucosal glands, as we
previously reported (10), or shed with exosomes contribute to
ATP depletion in CF airways. In this regard, Clayton and
coworkers (7) demonstrated that plasma membrane-tethered
ecto-nucleotidases associated with secreted exosomes ac-
counted for 20% of the total ATP-hydrolytic activity in pleural
effusions from patients with mesothelioma.
Similar to HBEC, [32P]ATP hydrolysis in CF sputum
resulted in formation of 32Pi (but not 32PPi), was markedly
reduced in the presence of POMs, and was not affected by
levamisol, strongly suggesting that ATP hydrolysis in CF lung
secretions is driven by ENTPDs. Based on the elevated number
of neutrophils present in CF sputa (Table 1), one speculation is
that ENTPD1, which is abundantly expressed in inflammatory
cells (8, 31), is shed from neutrophils and contributes to ATP
hydrolysis in CF lung secretions, as reported in COPD (18).
This hypothesis is apparently at odds with our data indicating
strong inhibition of ATP hydrolysis with POM-6, which inhib-
its ENTPD2 and 3 but, as mentioned above, had only a
partial effect on ENTPD1 (22). As discussed above for
HBEC, the molecular identification of the enzyme(s) re-
sponsible for ATP hydrolysis in lung secretions awaits the
development of ENTPD subtype-specific inhibitors.
In summary, we have identified polyoxometalates that mark-
edly reduce the hydrolysis of ATP by airway epithelial cells
and inflamed CF sputum. By increasing the stability of released
ATP in ASL, POM-5 restored ASL volume regulation in CF
cells, suggesting that ecto-ATPase inhibitors are candidate
tools to improve ASL/mucus hydration in CF. An ancillary
observation in our study is that ATPase activity is elevated in
CF lung secretions, suggesting that secreted/shed ATPases
contribute to the positive feedback cycle of ATP degradation,
airway/mucus dehydration, obstruction, and inflammation that
characterizes the CF airways.
ACKNOWLEDGMENTS
The authors are grateful to Dr. Scott Randell and the University of North
Carolina Tissue Core for supplying HBEC cultures, to Dr. José L. Boyer for
helpful comments, and to Eric Roe for editorial assistance. We thank Karin
Landrock for technical support in the synthesis of POM-4, POM-5, and
POM-6.
GRANTS
This study was supported by NIH Grants R56 HL136909, R01 HL125280,
UH3 HL123645, P01 HL110873, R01 HL136961, P30 DK065988-13, P01
HL108808, and Specialized Centers of Clinically Oriented Research (SCCOR)
P50-HL-084934, and by Cystic Fibrosis Foundation Grants LAZARO18P0,
LAZARO19GO, and BOUCHE15R0.
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the authors.
AUTHOR CONTRIBUTIONS
C.v.H., H.S., R.C.B., and E.R.L. conceived and designed research; C.v.H.,
B.B., W.H.A., L.C.M., H.D., N.E.A., S.D., H.S., R.C.B., and E.R.L. performed
experiments; C.v.H., B.B., W.H.A., A.C., L.C.M., W.K.O., H.D., H.S., R.C.B.,
and E.R.L. analyzed data; C.v.H., H.S., R.C.B., and E.R.L. interpreted results
of experiments; C.v.H., W.H.A., A.C., W.K.O., H.D., and E.R.L. prepared
figures; C.v.H., H.S., R.C.B., and E.R.L. drafted manuscript; C.v.H., B.B.,
W.H.A., A.C., L.C.M., S.D., H.S., R.C.B., and E.R.L. edited and revised
manuscript; C.v.H., B.B., W.H.A., A.C., L.C.M., W.K.O., H.D., N.E.A., S.D.,
H.S., R.C.B., and E.R.L. approved final version of manuscript.
REFERENCES
1. Abdullah LH, Coakley R, Webster MJ, Zhu Y, Tarran R, Radicioni
G, Kesimer M, Boucher RC, Davis CW, Ribeiro CMP. Mucin produc-
tion and hydration responses to mucopurulent materials in normal versus
cystic fibrosis airway epithelia. Am J Respir Crit Care Med 197: 481–491,
2018. doi:10.1164/rccm.201706-1139OC.
2. Anderson WH, Coakley RD, Button B, Henderson AG, Zeman KL,
Alexis NE, Peden DB, Lazarowski ER, Davis CW, Bailey S, Fuller F,
Almond M, Qaqish B, Bordonali E, Rubinstein M, Bennett WD,
Kesimer M, Boucher RC. The relationship of mucus concentration
(hydration) to mucus osmotic pressure and transport in chronic bronchitis.
Am J Respir Crit Care Med 192: 182–190, 2015. doi:10.1164/rccm.
201412-2230OC.
3. Baqi Y, Weyler S, Iqbal J, Zimmermann H, Müller CE. Structure-
activity relationships of anthraquinone derivatives derived from broma-
minic acid as inhibitors of ectonucleoside triphosphate diphosphohydro-
lases (E-NTPDases). Purinergic Signal 5: 91–106, 2009. doi:10.1007/
s11302-008-9103-5.
4. Burch LH, Picher M. E-NTPDases in human airways: regulation and
relevance for chronic lung diseases. Purinergic Signal 2: 399–408, 2006.
doi:10.1007/s11302-006-9001-7.
5. Button B, Okada SF, Frederick CB, Thelin WR, Boucher RC. Mecha-
nosensitive ATP release maintains proper mucus hydration of airways. Sci
Signal 6: ra46, 2013. doi:10.1126/scisignal.2003755.
6. Button B, Picher M, Boucher RC. Differential effects of cyclic and
constant stress on ATP release and mucociliary transport by human airway
epithelia. J Physiol 580: 577–592, 2007. doi:10.1113/jphysiol.2006.
126086.
7. Clayton A, Al-Taei S, Webber J, Mason MD, Tabi Z. Cancer exosomes
express CD39 and CD73, which suppress T cells through adenosine
production. J Immunol 187: 676–683, 2011. doi:10.4049/jimmunol.
1003884.
8. Corriden R, Chen Y, Inoue Y, Beldi G, Robson SC, Insel PA, Junger
WG. Ecto-nucleoside triphosphate diphosphohydrolase 1 (E-NTPDase1/
CD39) regulates neutrophil chemotaxis by hydrolyzing released ATP to
adenosine. J Biol Chem 283: 28480–28486, 2008. doi:10.1074/jbc.
M800039200.
9. Coyne CB, Ribeiro CM, Boucher RC, Johnson LG. Acute mechanism
of medium chain fatty acid-induced enhancement of airway epithelial
permeability. J Pharmacol Exp Ther 305: 440–450, 2003. doi:10.1124/
jpet.102.047654.
10. Donaldson SH, Lazarowski ER, Picher M, Knowles MR, Stutts MJ,
Boucher RC. Basal nucleotide levels, release, and metabolism in normal
and cystic fibrosis airways. Mol Med 6: 969–982, 2000. doi:10.1007/
BF03401831.
11. Donoso VM, Hernández F, Villalón T, Acuña-Castillo C, Pablo Hu-
idobro-Toro J. Pharmacological dissection of the cellular mechanisms
associated to the spontaneous and the mechanically stimulated ATP
release by mesentery endothelial cells: roles of thrombin and TRPV.
Purinergic Signal 14: 121–139, 2018. doi:10.1007/s11302-017-9599-7.
12. Dowd FJ, Li LS, Zeng W. Inhibition of rat parotid ecto-ATPase activity.
Arch Oral Biol 44: 1055–1062, 1999. doi:10.1016/S0003-9969(99)
00100-4.
13. Fausther M, Pelletier J, Ribeiro CM, Sévigny J, Picher M. Cystic
fibrosis remodels the regulation of purinergic signaling by NTPDase1
(CD39) and NTPDase3. Am J Physiol Lung Cell Mol Physiol 298:
L804–L818, 2010. doi:10.1152/ajplung.00019.2010.
14. Grygorczyk R, Hanrahan JW. CFTR-independent ATP release from
epithelial cells triggered by mechanical stimuli. Am J Physiol Cell Physiol
272: C1058–C1066, 1997. doi:10.1152/ajpcell.1997.272.3.C1058.
15. Henderson AG, Anderson WH, Ceppe A, Coakley RD, Button B,
Alexis NE, Peden DB, Lazarowski ER, Davis CW, Fuller F, Almond
M, Qaqish B, Kesimer M, Boucher RC. Mucus hydration in subjects
with stable chronic bronchitis: a comparison of spontaneous and induced
sputum. COPD 15: 572–580, 2018. doi:10.1080/15412555.2019.1566892.
16. Hoffmann C, Heine P, Pradel G, Kim YC, Jacobson KA, Zimmer-
mann H. Inhibition of ecto-apyrase and ecto-atpase by pyridoxal phos-
phate-related compounds. Drug Dev Res 51: 153–158, 2000. doi:10.1002/
1098-2299(200011)51:3153:AID-DDR3	3.0.CO;2-X.
17. Jia Y, Mathews CJ, Hanrahan JW. Phosphorylation by protein kinase C
is required for acute activation of cystic fibrosis transmembrane conduc-
tance regulator by protein kinase A. J Biol Chem 272: 4978–4984, 1997.
doi:10.1074/jbc.272.8.4978.
18. Lazar Z, Müllner N, Lucattelli M, Ayata CK, Cicko S, Yegutkin GG,
De Cunto G, Müller T, Meyer A, Hossfeld M, Sorichter S, Horvath I,
Virchow CJ, Robson SC, Lungarella G, Idzko M. NTPDase1/CD39 and
aberrant purinergic signalling in the pathogenesis of COPD. Eur Respir J
47: 254–263, 2016. doi:10.1183/13993003.02144-2014.
19. Lazarowski ER, Boucher RC. Purinergic receptors in airway epithelia.
Curr Opin Pharmacol 9: 262–267, 2009. doi:10.1016/j.coph.2009.02.004.
20. Lazarowski ER, Mason SJ, Clarke L, Harden TK, Boucher RC.
Adenosine receptors on human airway epithelia and their relationship to
chloride secretion. Br J Pharmacol 106: 774–782, 1992. doi:10.1111/j.
1476-5381.1992.tb14412.x.
21. Lazarowski ER, Tarran R, Grubb BR, van Heusden CA, Okada S,
Boucher RC. Nucleotide release provides a mechanism for airway surface
liquid homeostasis. J Biol Chem 279: 36855–36864, 2004. doi:10.1074/
jbc.M405367200.
22. Lee SY, Fiene A, Li W, Hanck T, Brylev KA, Fedorov VE, Lecka J,
Haider A, Pietzsch HJ, Zimmermann H, Sévigny J, Kortz U, Stephan
H, Müller CE. Polyoxometalates–potent and selective ecto-nucleotidase
inhibitors. Biochem Pharmacol 93: 171–181, 2015. doi:10.1016/j.bcp.
2014.11.002.
23. Lévesque SA, Lavoie EG, Lecka J, Bigonnesse F, Sévigny J. Specificity
of the ecto-ATPase inhibitor ARL 67156 on human and mouse ectonucle-
otidases. Br J Pharmacol 152: 141–150, 2007. doi:10.1038/sj.bjp.
0707361.
24. Müller CE, Iqbal J, Baqi Y, Zimmermann H, Röllich A, Stephan H.
Polyoxometalates–a new class of potent ecto-nucleoside triphosphate
diphosphohydrolase (NTPDase) inhibitors. Bioorg Med Chem Lett 16:
5943–5947, 2006. doi:10.1016/j.bmcl.2006.09.003.
25. Munkonda MN, Kauffenstein G, Kukulski F, Lévesque SA, Legendre
C, Pelletier J, Lavoie EG, Lecka J, Sévigny J. Inhibition of human and
mouse plasma membrane bound NTPDases by P2 receptor antagonists.
Biochem Pharmacol 74: 1524–1534, 2007. doi:10.1016/j.bcp.2007.07.
033.
26. Namkung W, Finkbeiner WE, Verkman AS. CFTR-adenylyl cyclase I
association responsible for UTP activation of CFTR in well-differentiated
primary human bronchial cell cultures. Mol Biol Cell 21: 2639–2648,
2010. doi:10.1091/mbc.e09-12-1004.
27. Okada SF, Nicholas RA, Kreda SM, Lazarowski ER, Boucher RC.
Physiological regulation of ATP release at the apical surface of human
airway epithelia. J Biol Chem 281: 22992–23002, 2006. doi:10.1074/jbc.
M603019200.
28. Okada SF, Ribeiro CM, Sesma JI, Seminario-Vidal L, Abdullah LH,
van Heusden C, Lazarowski ER, Boucher RC. Inflammation promotes
airway epithelial ATP release via calcium-dependent vesicular pathways.
Am J Respir Cell Mol Biol 49: 814–820, 2013. doi:10.1165/rcmb.2012-
0493OC.
29. Picher M, Boucher RC. Biochemical evidence for an ecto alkaline
phosphodiesterase I in human airways. Am J Respir Cell Mol Biol 23:
255–261, 2000. doi:10.1165/ajrcmb.23.2.4088.
30. Picher M, Burch LH, Boucher RC. Metabolism of P2 receptor
agonists in human airways: implications for mucociliary clearance and
cystic fibrosis. J Biol Chem 279: 20234 –20241, 2004. doi:10.1074/jbc.
M400305200.
31. Pulte ED, Broekman MJ, Olson KE, Drosopoulos JH, Kizer JR, Islam
N, Marcus AJ. CD39/NTPDase-1 activity and expression in normal
leukocytes. Thromb Res 121: 309–317, 2007. doi:10.1016/j.thromres.
2007.04.008.
32. Ransford GA, Fregien N, Qiu F, Dahl G, Conner GE, Salathe M.
Pannexin 1 contributes to ATP release in airway epithelia. Am J Respir
Cell Mol Biol 41: 525–534, 2009. doi:10.1165/rcmb.2008-0367OC.
33. Rao X, Huang X, Zhou Z, Lin X. An improvement of the 2ˆ(-delta delta
CT) method for quantitative real-time polymerase chain reaction data
analysis. Biostat Bioinforma Biomath 3: 71–85, 2013.
34. Reddy MM, Quinton PM, Haws C, Wine JJ, Grygorczyk R, Tabcha-
rani JA, Hanrahan JW, Gunderson KL, Kopito RR. Failure of the
cystic fibrosis transmembrane conductance regulator to conduct ATP.
Science 271: 1876–1879, 1996. doi:10.1126/science.271.5257.1876.
35. Seminario-Vidal L, Okada SF, Sesma JI, Kreda SM, van Heusden
CA, Zhu Y, Jones LC, O’Neal WK, Penuela S, Laird DW, Boucher
RC, Lazarowski ER. Rho signaling regulates pannexin 1-mediated ATP
release from airway epithelia. J Biol Chem 286: 26277–26286, 2011.
doi:10.1074/jbc.M111.260562.
36. Sesma JI, Kreda SM, Okada SF, van Heusden C, Moussa L, Jones LC,
O’Neal WK, Togawa N, Hiasa M, Moriyama Y, Lazarowski ER.
Vesicular nucleotide transporter regulates the nucleotide content in airway
epithelial mucin granules. Am J Physiol Cell Physiol 304: C976–C984,
2013. [Erratum in Am J Physiol Cell Physiol 306: C415, 2014.] doi:10.
1152/ajpcell.00371.2012.
37. Sesma JI, Weitzer CD, Livraghi-Butrico A, Dang H, Donaldson S,
Alexis NE, Jacobson KA, Harden TK, Lazarowski ER. UDP-glucose
promotes neutrophil recruitment in the lung. Purinergic Signal 12: 627–
635, 2016. doi:10.1007/s11302-016-9524-5.
38. Stephan H, Kubeil M, Emmerling F, Muller CE. Polyoxometalates as
versatile enzyme inhibitors. Eur J Inorg Chem 2013: 1585–1594, 2013.
doi:10.1002/ejic.201201224.
39. Tarran R, Button B, Boucher RC. Regulation of normal and cystic
fibrosis airway surface liquid volume by phasic shear stress. Annu Rev
Physiol 68: 543–561, 2006. doi:10.1146/annurev.physiol.68.072304.
112754.
40. Tarran R, Button B, Picher M, Paradiso AM, Ribeiro CM, Laz-
arowski ER, Zhang L, Collins PL, Pickles RJ, Fredberg JJ, Boucher
RC. Normal and cystic fibrosis airway surface liquid homeostasis. The
effects of phasic shear stress and viral infections. J Biol Chem 280:
35751–35759, 2005. doi:10.1074/jbc.M505832200.
41. Wall MJ, Wigmore G, Lopatár J, Frenguelli BG, Dale N. The novel
NTPDase inhibitor sodium polyoxotungstate (POM-1) inhibits ATP
breakdown but also blocks central synaptic transmission, an action inde-
pendent of NTPDase inhibition. Neuropharmacology 55: 1251–1258,
2008. doi:10.1016/j.neuropharm.2008.08.005.
42. Watt WC, Lazarowski ER, Boucher RC. Cystic fibrosis transmembrane
regulator-independent release of ATP. Its implications for the regulation
of P2Y2 receptors in airway epithelia. J Biol Chem 273: 14053–14058,
1998. doi:10.1074/jbc.273.22.14053.
43. Zimmermann H, Zebisch M, Sträter N. Cellular function and molecular
structure of ecto-nucleotidases. Purinergic Signal 8: 437–502, 2012.
doi:10.1007/s11302-012-9309-4.
